Form 4: Nascent Biotech CEO Sean Carrick Acquires 192,000 Shares

Nascent Biotech's CEO, Sean Carrick, acquired 192,000 shares of common stock on June 30, 2024, as part of his employment contract.

Summary

• On June 30, 2024, Sean Carrick, the President & CEO, Director, and a 10% Owner of Nascent Biotech Inc. (NBIO), acquired 192,000 shares of common stock.
• The acquisition was made at a price of $0.09 per share.
• This transaction increased Carrick's total beneficial ownership to 23,126,007 shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral. While insider buying can be seen as positive, this acquisition is part of an employment contract, making it a routine transaction rather than a discretionary investment.

Positives

• The CEO's acquisition of shares could be interpreted as a sign of confidence in the company's future prospects.

Industry Context

Form 4 filings are standard disclosures required by the SEC when insiders of a publicly traded company buy or sell the company's securities. These filings are closely watched by investors for insights into management's perspective on the company's value and future prospects.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment, as insider ownership is often viewed favorably.

Key Dates

Keywords

Nascent Biotech, NBIO, Sean Carrick, insider trading, Form 4, beneficial ownership, common stock, acquisition